Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Leuk Lymphoma ; 30(5-6): 449-58, 1998 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-9711907

RESUMO

Fas antigen (CD95) is a cell surface receptor belonging to the tumour necrosis factor/nerve growth factor superfamily and is able to induce apoptosis when triggered by its' natural ligand or an anti-Fas antibody. Fas expression is low on CD34+ bone marrow (BM) progenitor cells, but is increased by various cytokines in vitro. We investigated Fas expression on CD34+ cells from 39 peripheral blood progenitor cell (PBPC) harvests and from 5 normal BM harvests by dual colour flow cytometry to determine if Fas expression was altered during mobilisation. By including calibrated microbeads during flow cytometry, we quantified the number of Fas antigen molecules per cell. A low percentage of PBPC (22%) and normal BM (23%) CD34+ cells expressed Fas antigen. Fas expression varied on CD34+ cells from different diseases and the highest expression was found in ALL (52%). There was a significant three fold increase in the number of Fas molecules/cell expressed on CD34+ cells (PBPC 6,230 molecules/cell, BM 2,236; p = 0.0003). This level of expression was considerably less than that for CD3/CD19 lymphocytes (33,095 molecules/cell) and CD14 monocytes (47,467 molecules/cell) in the PBPC harvest. In conclusion, mobilisation including the use of growth of factors, has minimal effect on CD34 progenitor cell Fas expression.


Assuntos
Antígenos CD/metabolismo , Células-Tronco Hematopoéticas/metabolismo , Leucemia/metabolismo , Leucócitos Mononucleares/metabolismo , Linfoma/metabolismo , Receptor fas/biossíntese , Antígenos CD34/metabolismo , Apoptose , Células da Medula Óssea/metabolismo , Feminino , Citometria de Fluxo , Fator Estimulador de Colônias de Granulócitos/metabolismo , Humanos , Masculino
2.
Bone Marrow Transplant ; 21(5): 441-6, 1998 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-9535035

RESUMO

Quantifying progenitor cells in peripheral blood stem cell (PBSC) harvests by flow cytometric enumeration of CD34+ cells does not account for cell viability. Cell membrane asymmetry in early apoptosis exposes phosphatidylserine on the cell surface. This can be detected by staining with annexin V FITC. Apoptosis in 30 autologous PBSC harvests mobilised by cyclophosphamide + G-CSF or standard chemotherapy + G-CSF was analysed immediately after collection by dual-colour flow cytometry with CD34 PE and annexin V FITC. Harvests contained a median of 3.4 x 10(6)/kg (range 0.3-91.8) CD34+ cells. Of these 87.6% (range 30-96.5) were annexin V-. In 10% of harvests more than 50% of CD34+ cells were apoptotic. Differences in PBSC mobilisation or collection could not explain the variation in annexin V binding. Cyclophosphamide + G-CSF significantly increased the yield of CD34+ cells but did not increase apoptosis. Comparison of consecutive harvests showed no difference in the numbers of CD34+ cells collected but found a significant decrease in apoptotic CD34+ cells through multiple collections. Analysis of annexin V binding in PBSC harvests is a simple flow cytometry technique which gives additional information on the status of CD34+ progenitor cells.


Assuntos
Anexina A5 , Antígenos CD34 , Apoptose , Separação Celular/métodos , Citometria de Fluxo/métodos , Células-Tronco Hematopoéticas/fisiologia , Leucemia/fisiopatologia , Linfoma/fisiopatologia , Antígenos CD34/sangue , Antineoplásicos Alquilantes/uso terapêutico , Remoção de Componentes Sanguíneos , Sobrevivência Celular , Ciclofosfamida/uso terapêutico , Fluoresceína-5-Isotiocianato , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Humanos , Leucemia/tratamento farmacológico , Linfoma/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...